Jeffrey Turner, MD
Associate Professor Term; Co-Director Yale Hypertension Clinic, Nephrology; Nephrology Elective Director, Nephrology; Medical Director Davita Branford, Nephrology
Research & Publications
Biography
News
Research Summary
Dr. Turner's research interest focus on investigative treatments for chronic kidney disease, hypertension, and cardiorenal syndrome.
Coauthors
Selected Publications
- More Is Better!!Mehta P, Turner J. More Is Better!! Circulation Cardiovascular Quality And Outcomes 2024, e011063. PMID: 38873760, DOI: 10.1161/circoutcomes.124.011063.
- Serial direct sodium removal in patients with heart failure and diuretic resistanceRao V, Ivey‐Miranda J, Cox Z, Moreno‐Villagomez J, Ramos‐Mastache D, Neville D, Balkcom N, Asher J, Bellumkonda L, Bigvava T, Shaburishvili T, Bartunek J, Wilson F, Finkelstein F, Maulion C, Turner J, Testani J. Serial direct sodium removal in patients with heart failure and diuretic resistance. European Journal Of Heart Failure 2024, 26: 1215-1230. PMID: 38556717, DOI: 10.1002/ejhf.3196.
- Insulin Requirement and Infrainguinal Bypass Outcomes in Patients with Peripheral Arterial DiseaseAlameddine D, Satam K, Slade M, Wang H, Mena-Hurtado C, Turner J, Inzucchi S, Ochoa Chaar C. Insulin Requirement and Infrainguinal Bypass Outcomes in Patients with Peripheral Arterial Disease. Annals Of Vascular Surgery 2024, 102: 25-34. PMID: 38307234, DOI: 10.1016/j.avsg.2023.11.044.
- Empagliflozin in Heart Failure: Regional Nephron Sodium Handling EffectsRao V, Ivey-Miranda J, Cox Z, Moreno-Villagomez J, Maulion C, Bellumkonda L, Chang J, Field M, Wiederin D, Butler J, Collins S, Turner J, Wilson F, Inzucchi S, Wilcox C, Ellison D, Testani J. Empagliflozin in Heart Failure: Regional Nephron Sodium Handling Effects. Journal Of The American Society Of Nephrology 2023, 35: 189-201. PMID: 38073038, PMCID: PMC10843196, DOI: 10.1681/asn.0000000000000269.
- Current and Developing Technologies for BP MonitoringGunasekaran D, Turner J. Current and Developing Technologies for BP Monitoring. Current Cardiology Reports 2023, 25: 1151-1156. PMID: 37698819, DOI: 10.1007/s11886-023-01956-w.
- Intravenous Contrast is Associated with AKI in Patients with Stage 1–3 CKD: CONTurner J. Intravenous Contrast is Associated with AKI in Patients with Stage 1–3 CKD: CON. Kidney360 2023, 5: 648-650. PMID: 37287105, PMCID: PMC11146646, DOI: 10.34067/kid.0000000000000187.
- Drug‐Coated Balloon and Drug‐Eluting Stent Safety in Patients With Femoropopliteal and Severe Chronic Kidney DiseaseHanna J, Smolderen K, Castro‐Dominguez Y, Romain G, Lee M, Turner J, Mena‐Hurtado C. Drug‐Coated Balloon and Drug‐Eluting Stent Safety in Patients With Femoropopliteal and Severe Chronic Kidney Disease. Journal Of The American Heart Association 2023, 12: e028622. PMID: 36974774, PMCID: PMC10122876, DOI: 10.1161/jaha.122.028622.
- Carbon dioxide angiography during peripheral vascular interventions is associated with decreased cardiac and renal complications in patients with chronic kidney diseaseLee S, Ali S, Cardella J, Turner J, Guzman R, Dardik A, Ochoa Chaar C. Carbon dioxide angiography during peripheral vascular interventions is associated with decreased cardiac and renal complications in patients with chronic kidney disease. Journal Of Vascular Surgery 2023, 78: 201-208. PMID: 36948278, DOI: 10.1016/j.jvs.2023.03.029.
- In-Hospital Observation on Oral Diuretics After Treatment for Acute Decompensated Heart Failure: Evaluating the UtilityIvey-Miranda J, Rao V, Cox Z, Moreno-Villagomez J, Mahoney D, Maulion C, Bellumkonda L, Turner J, Collins S, Wilson F, Krumholz H, Testani J. In-Hospital Observation on Oral Diuretics After Treatment for Acute Decompensated Heart Failure: Evaluating the Utility. Circulation Heart Failure 2023, 16: e010206. PMID: 36896716, PMCID: PMC10186250, DOI: 10.1161/circheartfailure.122.010206.
- Use of drug-coated balloons and stents in patients with femoropopliteal artery disease and severe chronic kidney diseaseCastro-Dominguez Y, Smolderen K, Romain G, Turner J, Mena-Hurtado C. Use of drug-coated balloons and stents in patients with femoropopliteal artery disease and severe chronic kidney disease. Vascular Medicine 2023, 28: 150-152. PMID: 36710497, DOI: 10.1177/1358863x221148521.
- Predictors of Major Adverse Limb Events After Infrainguinal Bypass in Patients with DiabetesAlameddine D, Satam K, Slade M, Wang H, Mena-Hurtado C, Turner J, Inzucchi S, Chaar C. Predictors of Major Adverse Limb Events After Infrainguinal Bypass in Patients with Diabetes. American Heart Journal 2022, 254: 241. DOI: 10.1016/j.ahj.2022.10.026.
- Safety and Adequacy of Kidney Biopsy Procedure in Patients with ObesityQian L, Menez S, Hu D, Weinstein J, Melchinger H, Thiessen-Philbrook H, Luciano R, Turner J, Perazella M, Villalobos C, Shaw M, Wilson F, Parikh C, Moledina D. Safety and Adequacy of Kidney Biopsy Procedure in Patients with Obesity. Kidney360 2022, 4: 98-101. PMID: 36700910, PMCID: PMC10101611, DOI: 10.34067/kid.0006602022.
- Abstract 10491: Drug-Coated Balloon and Drug-Eluting Stent Safety in Patients With Femoropopliteal and Severe Chronic Kidney DiseaseHanna J, Smolderen K, Castro-Dominguez Y, Romain G, Lee M, Turner J, Mena-Hurtado C. Abstract 10491: Drug-Coated Balloon and Drug-Eluting Stent Safety in Patients With Femoropopliteal and Severe Chronic Kidney Disease. Circulation 2022, 146: a10491-a10491. DOI: 10.1161/circ.146.suppl_1.10491.
- CO2 Angiography During Peripheral Vascular Interventions Reduces Risk of Postcontrast Acute Kidney Injury and Cardiac Complications in Patients with Advanced Chronic Kidney DiseaseLee S, Ali S, Cardella J, Turner J, Guzman R, Dardik A, Chaar C. CO2 Angiography During Peripheral Vascular Interventions Reduces Risk of Postcontrast Acute Kidney Injury and Cardiac Complications in Patients with Advanced Chronic Kidney Disease. Journal Of Vascular Surgery 2022, 76: e101-e103. DOI: 10.1016/j.jvs.2022.07.081.
- OFF-LABEL USE OF DRUG COATED BALLOONS AND STENTS IN PATIENTS WITH FEMOROPOPLITEAL AND ADVANCED CHRONIC KIDNEY DISEASE. INSIGHTS FROM THE VASCULAR QUALITY INITIATIVEDominguez Y, Pichert M, Alabi O, Huang J, Qurat-Ul-Ain J, Arham A, Brice A, Ahmed Z, Chaar C, Stacy M, Turner J, Smolderen K, Hurtado C. OFF-LABEL USE OF DRUG COATED BALLOONS AND STENTS IN PATIENTS WITH FEMOROPOPLITEAL AND ADVANCED CHRONIC KIDNEY DISEASE. INSIGHTS FROM THE VASCULAR QUALITY INITIATIVE. Journal Of The American College Of Cardiology 2021, 77: 1012. DOI: 10.1016/s0735-1097(21)02371-8.
- Renal Disease in Older AdultsTurner J, Sharma D. Renal Disease in Older Adults. 2020, 265-276. DOI: 10.1007/978-3-319-47771-8_17.
- Cystatin C and Muscle Mass in Patients With Heart FailureIvey-Miranda JB, Inker LA, Griffin M, Rao V, Maulion C, Turner JM, Wilson FP, Tang WHW, Levey AS, Testani JM. Cystatin C and Muscle Mass in Patients With Heart Failure. Journal Of Cardiac Failure 2020, 27: 48-56. PMID: 32750487, PMCID: PMC8672303, DOI: 10.1016/j.cardfail.2020.07.013.
- Should Angiotensin-Converting Enzyme Inhibitors ever Be Used for the Management of Hypertension?Turner JM, Kodali R. Should Angiotensin-Converting Enzyme Inhibitors ever Be Used for the Management of Hypertension? Current Cardiology Reports 2020, 22: 95. PMID: 32648000, PMCID: PMC7344347, DOI: 10.1007/s11886-020-01352-8.
- Impact of Kidney Disease on Peripheral Arterial Interventions: A Systematic Review and Meta-AnalysisAnantha-Narayanan M, Sheikh AB, Nagpal S, Smolderen KG, Turner J, Schneider M, Llanos-Chea F, Mena-Hurtado C. Impact of Kidney Disease on Peripheral Arterial Interventions: A Systematic Review and Meta-Analysis. American Journal Of Nephrology 2020, 51: 527-533. PMID: 32570255, DOI: 10.1159/000508575.
- Empagliflozin in Heart FailureGriffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C, Suda N, Siwakoti K, Ahmad T, Jacoby D, Riello R, Bellumkonda L, Cox Z, Collins S, Jeon S, Turner JM, Wilson FP, Butler J, Inzucchi SE, Testani JM. Empagliflozin in Heart Failure. Circulation 2020, 142: 1028-1039. PMID: 32410463, PMCID: PMC7521417, DOI: 10.1161/circulationaha.120.045691.
- Real World Use of Hypertonic Saline in Refractory Acute Decompensated Heart Failure A U.S. Center’s ExperienceGriffin M, Soufer A, Goljo E, Colna M, Rao VS, Jeon S, Raghavendra P, D'Ambrosi J, Riello R, Coca SG, Mahoney D, Jacoby D, Ahmad T, Chen M, Tang WHW, Turner J, Mullens W, Wilson FP, Testani JM. Real World Use of Hypertonic Saline in Refractory Acute Decompensated Heart Failure A U.S. Center’s Experience. JACC Heart Failure 2020, 8: 199-208. PMID: 32035891, PMCID: PMC7814403, DOI: 10.1016/j.jchf.2019.10.012.
- First-in-Human Experience With Peritoneal Direct Sodium Removal Using a Zero-Sodium SolutionRao VS, Turner JM, Griffin M, Mahoney D, Asher J, Jeon S, Yoo PS, Boutagy N, Feher A, Sinusas A, Wilson FP, Finkelstein F, Testani JM. First-in-Human Experience With Peritoneal Direct Sodium Removal Using a Zero-Sodium Solution. Circulation 2020, 141: 1043-1053. PMID: 31910658, PMCID: PMC7331276, DOI: 10.1161/circulationaha.119.043062.
- Effect on Survival of Concurrent Hemoconcentration and Increase in Creatinine During Treatment of Acute Decompensated Heart FailureGriffin M, Rao VS, Fleming J, Raghavendra P, Turner J, Mahoney D, Wettersten N, Maisel A, Ivey-Miranda JB, Inker L, Tang WHW, Wilson FP, Testani JM. Effect on Survival of Concurrent Hemoconcentration and Increase in Creatinine During Treatment of Acute Decompensated Heart Failure. The American Journal Of Cardiology 2019, 124: 1707-1711. PMID: 31601358, PMCID: PMC6959849, DOI: 10.1016/j.amjcard.2019.08.034.
- Natriuretic Response Is Highly Variable and Associated With 6-Month Survival Insights From the ROSE-AHF TrialHodson DZ, Griffin M, Mahoney D, Raghavendra P, Ahmad T, Turner J, Wilson FP, Tang WHW, Rao VS, Collins SP, Mullens W, Testani JM. Natriuretic Response Is Highly Variable and Associated With 6-Month Survival Insights From the ROSE-AHF Trial. JACC Heart Failure 2019, 7: 383-391. PMID: 31047017, PMCID: PMC6501816, DOI: 10.1016/j.jchf.2019.01.007.
- Serum and Urine Albumin and Response to Loop Diuretics in Heart FailureCharokopos A, Griffin M, Rao VS, Inker L, Sury K, Asher J, Turner J, Mahoney D, Cox ZL, Wilson FP, Testani JM. Serum and Urine Albumin and Response to Loop Diuretics in Heart Failure. Clinical Journal Of The American Society Of Nephrology 2019, 14: cjn.11600918. PMID: 31010938, PMCID: PMC6500945, DOI: 10.2215/cjn.11600918.
- Development of a Direct Peritoneal Sodium Removal Technique with Salt Free SolutionMahoney D, Rao V, Asher J, Struyk G, Boutagy N, Feher A, Turner J, Sinusas A, Testani J. Development of a Direct Peritoneal Sodium Removal Technique with Salt Free Solution. Journal Of Cardiac Failure 2018, 24: s34. DOI: 10.1016/j.cardfail.2018.07.099.
- Barriers to Advance Care Planning in End-Stage Renal Disease: Who is to Blame, and What Can be Done?Kelley AT, Turner J, Doolittle B. Barriers to Advance Care Planning in End-Stage Renal Disease: Who is to Blame, and What Can be Done? The New Bioethics 2018, 24: 150-157. PMID: 29513084, DOI: 10.1080/20502877.2018.1438772.
- Blood pressure targets for hemodialysis patientsTurner JM, Peixoto AJ. Blood pressure targets for hemodialysis patients. Kidney International 2017, 92: 816-823. PMID: 28938954, DOI: 10.1016/j.kint.2017.01.038.
- Nutritional Supplements for the Treatment of Hypertension: A Practical Guide for CliniciansTurner JM, Spatz ES. Nutritional Supplements for the Treatment of Hypertension: A Practical Guide for Clinicians. Current Cardiology Reports 2016, 18: 126. PMID: 27796863, DOI: 10.1007/s11886-016-0806-x.
- We Avoid RAAS Inhibitors in PD Patients with Residual Renal FunctionTurner JM. We Avoid RAAS Inhibitors in PD Patients with Residual Renal Function. Seminars In Dialysis 2016, 29: 265-267. PMID: 27061273, DOI: 10.1111/sdi.12488.
- Do Any Patients with Acute Decompensated Heart Failure and Acute Cardio‐Renal Syndrome Benefit from Ultrafiltration?Turner JM, Testani JM. Do Any Patients with Acute Decompensated Heart Failure and Acute Cardio‐Renal Syndrome Benefit from Ultrafiltration? Seminars In Dialysis 2014, 27: 231-233. PMID: 24620858, DOI: 10.1111/sdi.12221.
- Acid Base DisordersTurner JM, Peixoto AJ. Acid Base Disorders. Pastores SM. In: Adult Multiprofessional Critical Care Review. 2014
- Loop Diuretic EfficiencyTestani JM, Brisco MA, Turner JM, Spatz ES, Bellumkonda L, Parikh CR, Tang WH. Loop Diuretic Efficiency. Circulation Heart Failure 2013, 7: 261-270. PMID: 24379278, PMCID: PMC4386906, DOI: 10.1161/circheartfailure.113.000895.
- Treatment of hyperkalemiaTurner J. Treatment of hyperkalemia. Expert Opinion On Orphan Drugs 2013, 1: 359-371. DOI: 10.1517/21678707.2013.794692.
- Treatment of chronic kidney disease.Turner JM, Bauer C, Abramowitz MK, Melamed ML, Hostetter TH. Treatment of chronic kidney disease. Kidney International 2012, 81: 351-62. PMID: 22166846, DOI: 10.1038/ki.2011.380.
- Acute kidney injury as a causal factor in mortality associated with hepatorenal syndrome.Deshpande P, Rausa K, Turner J, Johnson M, Golestaneh L. Acute kidney injury as a causal factor in mortality associated with hepatorenal syndrome. Hepatology International 2011, 5: 751-8. PMID: 21484115, DOI: 10.1007/s12072-011-9269-8.
- Imaging Patients with Kidney Disease-Weighing the Risks and BenefitsTurner JM, Perazella MA. Imaging Patients with Kidney Disease-Weighing the Risks and Benefits.US Nephrology.2011;6:131-137
Clinical Trials
Conditions | Study Title |
---|---|
Diseases of the Kidney & Urinary Tract | A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease (FIND-CKD) |
Hypertension | TARGET BP I Clinical Trial (TARGET BP I) |